ALZCUR AlzeCure Pharma AB (publ)
AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops small-molecule drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer's disease, sleep disorders, depression, traumatic brain injuries, and Parkinson's disease, which is in phase I clinical trial; ACD857 and ACD680 that are in preclinical trial for the treatment of Alzheimer's disease; ACD440, a TRPV1 antagonist, which is in phase II clinical trial for neuropathic pain indications; and ACD137 negative allosteric modulator (NAM) of TrkA receptors for osteoarthritic pain indications, which is in preclinical phase. AlzeCure Pharma AB (publ) was founded in 2012 and is based in Huddinge, Sweden.…
Industry Peers
BiotechnologyKey Statistics
About AlzeCure Pharma (STO: ALZCUR)
›
AlzeCure Pharma (STO: ALZCUR) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 10 employees.
The shares were at 5.840 SEK on 19 November 2026, up 193.5% over 52 weeks. Its 52-week range is 1.300 SEK to 8.680 SEK: the price is 32.7% below the high and 349.2% above the low.
At a market capitalisation of 671.10M SEK, it trades at 8.5 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a discount of 75% for ALZCUR.
AlzeCure Pharma reports return on equity of -144.8% and an operating margin of 59.1%.
It holds more cash than debt, a net cash position of 230.22M SEK. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 13.00 SEK is 122.6% above the current price.